You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Refractory MCL

Showing 1 - 25 of 8,999
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma Trial in Houston (Biospecimen Collection, Follow-Up)

Recruiting
  • Recurrent Mantle Cell Lymphoma
  • Refractory Mantle Cell Lymphoma
  • Biospecimen Collection
  • Follow-Up
  • Houston, Texas
    M D Anderson Cancer Center
Dec 5, 2022

Mantle Cell Lymphoma Trial in China (400mg of TQB3909 tablets, 600mg of TQB3909 tablets)

Recruiting
  • Mantle Cell Lymphoma
  • 400mg of TQB3909 tablets
  • 600mg of TQB3909 tablets
  • Beijing, Beijing, China
  • +27 more
Oct 26, 2023

Mantle Cell Lymphoma, Refractory Lymphoma Trial in Boston (Acalabrutinib, Venetoclax, Obinutuzumab)

Recruiting
  • Mantle Cell Lymphoma
  • Refractory Lymphoma
  • Boston, Massachusetts
  • +1 more
Aug 8, 2022

Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma (MCL), Relapsed Mantle Cell Lymphoma Trial (BGB-11417)

Not yet recruiting
  • Mantle Cell Lymphoma
  • +2 more
  • (no location specified)
Jul 25, 2022

Relapsed or Refractory B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL) Trial in Beijing

Recruiting
  • Relapsed or Refractory B-cell Lymphoma
  • +6 more
  • Beijing, China
    Beijing Cancer Hospital
Feb 6, 2023

Blastoid Variant Mantle Cell Lymphoma, CCND1 Protein Overexpression, CD20 Positive Trial in Houston (Acalabrutinib, Venetoclax)

Recruiting
  • Blastoid Variant Mantle Cell Lymphoma
  • +8 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 5, 2022

Aggressive B-Cell Non-Hodgkin's Lymphoma, Aggressive B-Cell NHL, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Trial

Not yet recruiting
  • Aggressive B-Cell Non-Hodgkin's Lymphoma
  • +4 more
  • (no location specified)
Dec 16, 2022

Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma Trial in Houston (Eprenetapopt, Venetoclax)

Withdrawn
  • Recurrent Mantle Cell Lymphoma
  • Refractory Mantle Cell Lymphoma
  • Houston, Texas
    M D Anderson Cancer Center
Feb 23, 2022

Lymphoma, Mantle-Cell, Recurrent Lymphoma, Mantle-Cell Trial in United States (ABT-199 and Ibrutinib Combination)

Completed
  • Lymphoma, Mantle-Cell
  • Recurrent Lymphoma, Mantle-Cell
  • ABT-199 and Ibrutinib Combination
  • Duarte, California
  • +3 more
May 22, 2022

Mantle Cell Lymphoma Trial in Beijing (DTRMWXHS-12)

Active, not recruiting
  • Mantle Cell Lymphoma
  • Beijing, China
    Peking University Cancer Hospital
Aug 18, 2021

Refractory Mantle Cell Lymphoma, Relapsed Mantle Cell Lymphoma Trial in China (Zanubrutinib)

Completed
Has Results
  • Refractory Mantle Cell Lymphoma
  • Relapsed Mantle Cell Lymphoma
  • Beijing, Beijing, China
  • +13 more
Oct 8, 2021

Mantle Cell Lymphoma Trial in Hackensack (Lenalidomide, Ibrutinib, Rituximab)

Active, not recruiting
  • Mantle Cell Lymphoma
  • Hackensack, New Jersey
    The Cancer Center at Hackensack University Medical Center
May 3, 2022

Mantle Cell Lymphoma, MCL Trial in United States (Tafasitamab, Lenalidomide)

Recruiting
  • Mantle Cell Lymphoma
  • MCL
  • Basking Ridge, New Jersey
  • +6 more
Mar 27, 2023

Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Diffuse Large B Cell Lymphoma (DLBCL) Trial in Manchester,

Recruiting
  • Chronic Lymphocytic Leukemia (CLL)
  • +7 more
  • Manchester, United Kingdom
  • +2 more
Aug 11, 2022

Non Hodgkin Lymphoma (NHL), Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL) Trial in Milwaukee (8/12-Day

Recruiting
  • Non Hodgkin Lymphoma (NHL)
  • +6 more
  • 8/12-Day Production of Car-T Cells
  • +2 more
  • Milwaukee, Wisconsin
    Medical College of Wisconsin and Froedtert Hospital
Jul 1, 2022

Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma Trial in Duarte (Acalabrutinib,

Recruiting
  • Recurrent Mantle Cell Lymphoma
  • Refractory Mantle Cell Lymphoma
  • Acalabrutinib
  • CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes
  • Duarte, California
    City of Hope Comprehensive Cancer Center
Jun 16, 2022

CLL/SLL Trial in Worldwide (Epcoritamab, Venetoclax)

Not yet recruiting
  • CLL/SLL
  • Antwerpen, Belgium
  • +23 more
Mar 28, 2023

Follicular Lymphoma Patients (Phase IB), Follicular and Agressive (DLBCL&MCL) B-cell Lymphoma Patients (Phase II) Trial in

Active, not recruiting
  • Follicular Lymphoma Patients (Phase IB)
  • Follicular and Agressive (DLBCL&MCL) B-cell Lymphoma Patients (Phase II)
  • Lenalidomide and GA101
  • Antwerpen, Belgium
  • +24 more
Apr 6, 2022

Mantle Cell Lymphoma (MCL) Trial in Japan (Ibrutinib, Venetoclax)

Active, not recruiting
  • Mantle Cell Lymphoma (MCL)
  • Nagoya-shi, Aichi, Japan
  • +11 more
Apr 4, 2022

Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma Trial in Worldwide (MIK665)

Completed
  • Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma
  • Houston, Texas
  • +7 more
Jul 27, 2021

Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL) Trial in United States (voruciclib

Recruiting
  • Follicular Lymphoma (FL)
  • +6 more
  • voruciclib monotherapy
  • voruciclib and venetoclax
  • Duarte, California
  • +10 more
Aug 10, 2022

CCND1 Positive, CCND2 Positive, CCND3 Positive Trial in Houston (drug, other, biological)

Active, not recruiting
  • CCND1 Positive
  • +6 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 11, 2022

Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Waldenstrom Macroglobulinemia (WM) Trial in United States

Recruiting
  • Chronic Lymphocytic Leukemia (CLL)
  • +6 more
  • Duarte, California
  • +10 more
Jul 14, 2022

Relapsed Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma Trial in Italy (Consolidation with ADCT-402 (loncastuximab

Recruiting
  • Relapsed Mantle Cell Lymphoma
  • Refractory Mantle Cell Lymphoma
  • Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy (R-BAC, Rituximab - Bendamustine, Ara-C))
  • Brescia, Italy
  • +19 more
Apr 22, 2022

Hodgkin Lymphoma Trial in Belgium, Denmark, Netherlands (gemcitabine, cisplatin and tislelizumab)

Not yet recruiting
  • Hodgkin Lymphoma
  • gemcitabine, cisplatin and tislelizumab
  • Brussels, Belgium
  • +14 more
Aug 12, 2022